ICON plc, a global CRO, has been re-selected by the Biomedical Advanced Research and Development Authority (BARDA) to continue being part of its exclusive Medical Countermeasures Clinical Studies Network (CSN).

BARDA, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, is responsible for developing medical countermeasures to secure the U.S. against chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. The CSN provides BARDA partners with vital technical and regulatory assistance to develop vaccines, therapeutics, diagnostics, and medical devices to prevent or treat the medical consequences of these threats.

ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.

“We are proud to be re-selected for this important work, and to play our part in developing medical countermeasures to save lives, and keep people safe,” said Dr James Cummings, President, ICON Government and Public Health Solutions. “ICON is a world-leader in drug development, and our teams have worked on vaccines and therapeutics for every major pandemic in the last 30 years. We look forward to continuing to make our clinical expertise available to BARDA partners as part of the Medical Countermeasures Clinical Studies Network.”